| 1 |
34969747 | Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review. | 2022 Jan |
2 |
| 2 |
33563752 | Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. | 2021 Apr |
1 |
| 3 |
34458148 | Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells. | 2021 |
5 |
| 4 |
32901840 | Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells. | 2020 Nov |
1 |
| 5 |
31675556 | Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib. | 2019 Dec |
2 |
| 6 |
29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May |
1 |
| 7 |
29291014 | Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. | 2017 Dec 5 |
1 |
| 8 |
26921392 | Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. | 2016 May |
1 |
| 9 |
24259629 | Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. | 2013 Dec |
1 |